BRPI0408442A - método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato - Google Patents

método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato

Info

Publication number
BRPI0408442A
BRPI0408442A BRPI0408442-0A BRPI0408442A BRPI0408442A BR PI0408442 A BRPI0408442 A BR PI0408442A BR PI0408442 A BRPI0408442 A BR PI0408442A BR PI0408442 A BRPI0408442 A BR PI0408442A
Authority
BR
Brazil
Prior art keywords
phenyl
amino
methylpropanothioate
ethylbutyl
increasing
Prior art date
Application number
BRPI0408442-0A
Other languages
English (en)
Inventor
Yasuo Urata
Tomohiro Ishikawa
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BRPI0408442A publication Critical patent/BRPI0408442A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO PARA AUMENTO DA BIODISPONIBILIDADE ORAL DE S-¢2-(¢¢1-(2-ETILBUTIL)CICLOHEXIL!CARBONIL!AMINO)FENIL!2- METILPROPANOTIOATO". A presente invenção refere-se a um método de aumento da biodisponibilidade da forma ativa de S-¢2-(¢¢1-(2-etilbutil)ciclohexil!carbonil!amino)fenil!2-metilpropanotioat o através da administração de uma quantidade terapeuticamente eficaz da droga com alimento. A invenção também provê um kit compreendendo uma composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz de S-¢2-(¢¢1-(2-etilbutil)ciclohexil!carbonil!amino)fenil!2-metilpropanotioat o e um veículo farmaceuticamente aceitável, informação de prescrição e um recipiente, onde a informação de prescrição inclui aviso a um paciente com relação à administração da droga com alimento para melhorar a biodisponibilidade.
BRPI0408442-0A 2003-03-17 2004-03-17 método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato BRPI0408442A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45529303P 2003-03-17 2003-03-17
US46052103P 2003-04-04 2003-04-04
US47720203P 2003-06-10 2003-06-10
PCT/JP2004/003589 WO2004082675A1 (en) 2003-03-17 2004-03-17 Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate

Publications (1)

Publication Number Publication Date
BRPI0408442A true BRPI0408442A (pt) 2006-04-04

Family

ID=33033150

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408442-0A BRPI0408442A (pt) 2003-03-17 2004-03-17 método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato

Country Status (11)

Country Link
US (2) US7276536B2 (pt)
EP (1) EP1603554A1 (pt)
JP (1) JP2006520810A (pt)
KR (1) KR20050110017A (pt)
AU (1) AU2004222436A1 (pt)
BR (1) BRPI0408442A (pt)
CA (1) CA2519458A1 (pt)
CO (1) CO5700729A2 (pt)
MX (1) MXPA05009976A (pt)
NO (1) NO20054739L (pt)
WO (1) WO2004082675A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
BRPI0408442A (pt) 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20100227916A1 (en) * 2006-05-19 2010-09-09 Somaxon Pharmaceuticals, Inc N-desmethyl-doxepin and methods of using the same to treat sleep disorders
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080058408A1 (en) 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US8513299B2 (en) 2006-05-19 2013-08-20 Pernix Sleep, Inc. Methods of using low-dose doxepin for the improvement of sleep
CA2693992C (en) * 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
WO2008085567A1 (en) * 2006-10-04 2008-07-17 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
CA2721133C (en) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
WO2010066593A1 (en) * 2008-12-08 2010-06-17 F. Hoffmann-La Roche Ag Combined drug administration
MY164729A (en) 2010-11-04 2018-01-30 Hoffmann La Roche A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
MX370538B (es) 2013-03-27 2019-12-17 Hoffmann La Roche Marcadores genéticos para la predicción de respuesta a la terápia.
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576830A (en) 1966-08-12 1971-04-27 Sumitomo Chemical Co Amides containing sulfur
JPS4511132Y1 (pt) 1966-09-26 1970-05-19
JPS4735786U (pt) 1971-05-10 1972-12-20
US4346277A (en) 1979-10-29 1982-08-24 Eaton Corporation Packaged electrical heating element
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4940727A (en) 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4740438A (en) 1986-12-10 1988-04-26 Eastman Kodak Company Organic disulfides as image dye stabilizers
US4853319A (en) 1986-12-22 1989-08-01 Eastman Kodak Company Photographic silver halide element and process
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
JPH01278543A (ja) 1988-04-30 1989-11-08 Sanshin Chem Ind Co Ltd ゴム組成物
JPH01321432A (ja) 1988-06-22 1989-12-27 Konica Corp ハロゲン化銀写真感光材料
JPH0223338A (ja) 1988-07-12 1990-01-25 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5118583A (en) 1988-10-12 1992-06-02 Mitsubishi Paper Mills Limited Processing composition for printing plate
DE3835198A1 (de) 1988-10-15 1990-04-19 Bayer Ag Verfahren zur herstellung von kautschukvulkanisaten mit verringerten hystereseverlusten und formkoerper aus diesen vulkanisaten
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JPH03226750A (ja) 1990-01-31 1991-10-07 Konica Corp ハロゲン化銀カラー写真感光材料
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
FR2665450B1 (fr) 1990-08-01 1994-04-08 Rhone Poulenc Chimie Procede de preparation de dispersions aqueuses de copolymeres.
GB9017711D0 (en) 1990-08-13 1990-09-26 May & Baker Ltd New compositions of matter
GB9017710D0 (en) 1990-08-13 1990-09-26 May & Baker Ltd New compositions of matter
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9120131D0 (en) 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
US5519001A (en) 1991-12-19 1996-05-21 Southwest Foundation For Biomedical Research CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
US5217859A (en) 1992-04-16 1993-06-08 Eastman Kodak Company Aqueous, solid particle dispersions of dichalcogenides for photographic emulsions and coatings
US5219721A (en) 1992-04-16 1993-06-15 Eastman Kodak Company Silver halide photographic emulsions sensitized in the presence of organic dichalcogenides
ES2133158T3 (es) 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5350667A (en) 1993-06-17 1994-09-27 Eastman Kodak Company Photographic elements containing magenta couplers and process for using same
US5534529A (en) 1993-06-30 1996-07-09 Sankyo Company, Limited Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
JP3894949B2 (ja) 1993-06-30 2007-03-22 ザ、ウェルカム、ファンデーション、リミテッド 抗アテローム性動脈硬化症ジアリール化合物
US5446207A (en) 1993-09-01 1995-08-29 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
US5459154A (en) 1993-11-08 1995-10-17 American Home Products Corporation N-hydroxyureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein
US5405969A (en) 1993-12-10 1995-04-11 Eastman Kodak Company Manufacture of thioether compounds
JP3304189B2 (ja) 1994-03-18 2002-07-22 マツダ株式会社 加硫スクラップゴムを含有する成形用ゴム組成物及びその製造方法
US5654134A (en) 1994-05-18 1997-08-05 Fuji Photo Film Co., Ltd. Silver halide emulsion
DE4428457C1 (de) 1994-08-11 1995-10-05 Bayer Ag Geformte, paraffinhaltige Mastiziermittel
US6001555A (en) 1994-09-23 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein
EP0733061A1 (en) 1994-11-12 1996-09-25 LG Chemical Limited Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents
US5698564A (en) 1994-12-16 1997-12-16 Nisshin Flour Milling Co., Ltd. Diphenyl disulfide compounds
WO1996030761A1 (en) 1995-03-27 1996-10-03 Warner-Lambert Company Method and apparatus for simultaneously testing a plurality of compounds to detect their activity
BR9609872A (pt) 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
JPH0959155A (ja) 1995-08-23 1997-03-04 Kaken Pharmaceut Co Ltd コレステリルエステル転送反応阻害剤
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
ES2127690B1 (es) 1996-08-02 2000-01-01 Univ Granada Procedimientos de obtencion de (+)-puupehenona a partir de terpenoides biciclicos.
TR199901180T2 (xx) 1996-11-27 1999-08-23 Pfizer Inc. Apo B-Salg�lama/MTP inhibit�r amidler.
DE19704243A1 (de) 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US6605624B1 (en) 1998-02-13 2003-08-12 Pharmacia Corporation Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6080778A (en) 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6692909B1 (en) 1998-04-01 2004-02-17 Whitehead Institute For Biomedical Research Coding sequence polymorphisms in vascular pathology genes
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
JP3924124B2 (ja) 1998-09-25 2007-06-06 ファルマシア・コーポレーション コレステロールエステル輸送タンパク質活性阻害に有効な置換された多環アリールおよびヘテロアリール第三級ヘテロアルキルアミン
CA2345108A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
AU3103800A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
AU2157500A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
BR9916486A (pt) 1998-12-23 2002-02-05 Searle Llc Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
US6458850B1 (en) 1998-12-23 2002-10-01 G.D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
AU751849B2 (en) 1999-03-08 2002-08-29 Kitasato Institute, The Substances WK-5344A and WK-5344B and process for producing the same
WO2001018250A2 (en) 1999-09-10 2001-03-15 Whitehead Institute For Biomedical Research Single nucleotide polymorphisms in genes
US6451830B1 (en) 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
AU2001233299A1 (en) 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6982348B2 (en) 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
BRPI0408442A (pt) * 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合

Also Published As

Publication number Publication date
WO2004082675A8 (en) 2005-11-03
WO2004082675A1 (en) 2004-09-30
US7276536B2 (en) 2007-10-02
KR20050110017A (ko) 2005-11-22
US20080045599A1 (en) 2008-02-21
AU2004222436A1 (en) 2004-09-30
US20040242683A1 (en) 2004-12-02
NO20054739D0 (no) 2005-10-14
MXPA05009976A (es) 2005-11-04
EP1603554A1 (en) 2005-12-14
CA2519458A1 (en) 2004-09-30
NO20054739L (no) 2005-12-14
JP2006520810A (ja) 2006-09-14
CO5700729A2 (es) 2006-11-30

Similar Documents

Publication Publication Date Title
MXPA05009976A (es) Metodo para incrementar la biodisponibilidad oral del 2-metilpropantioato de s-[2-([[1- 2-etilbutil) ciclohexil] carbonil] amino) fenilo].
EP1477119A4 (en) METHOD FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
KR102424765B1 (ko) 외상후 스트레스 장애의 치료 방법
Bauer et al. Assessment of preemptive analgesia with ibuprofen coadministered or not with dexamethasone in third molar surgery: a randomized double-blind controlled clinical trial
ATE420632T1 (de) Titrationsdosierschema für kontrolliert freigesetztes tramadol
BRPI0406486A (pt) Dispositivo de administração para medicamento fluido
ATE306266T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
ATE450252T1 (de) Arzneimittel-mikroteilchen
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
BR0107564A (pt) Composição de gliburida
EP1638639A4 (en) DRUG DELIVERY METHOD AND METHOD
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
EP2043637A4 (en) METHOD AND MEDICAMENTS FOR THE ADMINISTRATION OF IBUPROFEN
BRPI0512756A (pt) composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
AU2003243439A1 (en) Medical device for intra-lumenal delivery of pharmaceutical agents
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
US20210361598A1 (en) Compounds for prevention and treatment of post-intensive care cognitive dysfunction and cognitive dysfunction resulting from respiratory distress
US20230404947A1 (en) Compositions, methods of treatment, and containers including compositions
JP2023546294A (ja) Ｇｐ１３０シグナル伝達経路の小分子モジュレーター、局所製剤およびその使用方法
TN2022000289A1 (en) Novel compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2н-chromen-2-on-7-yl sulphate and use thereof
JP7250698B2 (ja) 中枢神経系の変性疾患及び／又はリソソーム蓄積疾患を予防及び／又は治療するための新規組成物
BR0213340A (pt) Formulação de medicamento sólida para um derivado de piperazinuréia
ATE446759T1 (de) Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
US12245997B2 (en) Endoxifen for the treatment of bipolar I disorder

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.